SCHEMBL8206282

SCHEMBL8206282

COc1ccc(S(=O)(=O)N2CCCN(c3nc(Cc4cccc(OC)c4)ns3)CC2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
KMT2A Q03164 3/20 0.53
POLB P06746 2/20 0.53
GAA P10253 2/20 0.53
MEN1 O00255 2/20 0.53
TSHR P16473 3/20 0.52
ALOX15 P16050 1/20 0.52
MAPT P10636 3/20 0.50
USP2 O75604 2/20 0.49
HSD17B10 Q99714 2/20 0.49
RECQL P46063 1/20 0.49
LMNA P02545 4/20 0.48
HTT P42858 3/20 0.48
ATM Q13315 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
PKM P14618 3/20 0.47
MAPK1 P28482 1/20 0.46
HPGD P15428 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
NPC1 O15118 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1024125 0.96 LMNA (0.52) ALDH1A1KMT2APOLBGAAMEN1
SCHEMBL12569071 0.90 LMNA (0.62) ALDH1A1KMT2APOLBGAAMEN1
SCHEMBL8203108 0.90 MAPT (0.49) ALDH1A1KMT2APOLBGAAMEN1
SCHEMBL12569058 0.89 KMT2A (0.52) ALDH1A1KMT2APOLBTSHRMAPT
SCHEMBL2012046 0.88 ALDH1A1 (0.58) ALDH1A1KMT2APOLBTSHRMAPT
SCHEMBL2004686 0.88 PKM (0.58) ALDH1A1KMT2APOLBTSHRMAPT
SCHEMBL12569067 0.86 PKM (0.56) ALDH1A1KMT2APOLBTSHRMAPT
SCHEMBL3059823 0.85 MAPT (0.44) ALDH1A1KMT2APOLBGAAMEN1
SCHEMBL3064241 0.85 HTR6 (0.47) ALDH1A1KMT2APOLBGAAMEN1
SCHEMBL2012893 0.83 KMT2A (0.53) ALDH1A1KMT2APOLBTSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US disclosed
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US disclosed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US disclosed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US disclosed
WO-2008061781-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES SNCA, PARK7, PRNP ALDH1A1 608/4885KMT2A 3893/4885POLB 2907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.